Insider Ledger
RenovoRx, Inc. (RNXT) insider buying and SEC filings
RenovoRx, Inc. · CIK 1574094
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Surgical & Medical Instruments & Apparatus
- State of incorporation
- DE
- Fiscal year end
- Dec 31
Insider activity in the last 12 months
Bought
$58K
Insiders who bought
2
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$0
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| May 19, 2026 | Open-market purchase | Mark Voll (CFO) bought 25,000 shares at $0.7900 ($20K) in an open-market purchase. Holdings up 21% to 142,380 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 21, 2026 |
| Mar 20, 2026 | Other purchase | Laurence Marton (Director) bought 14,580 shares in 2 share classes indirectly (by retirement or benefit plan); the filing does not report a price. New position of 9,720 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 24, 2026 |
| Mar 20, 2026 | Other purchase | Shaun Bagai (CEO and Director) bought 36,450 shares in 2 share classes indirectly (by trust); the filing does not report a price. Holdings of Common Stock by trust up 8% to 313,357 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 24, 2026 |
| Mar 20, 2026 | Other purchase | Mark Voll (CFO) bought 145,800 shares in 2 share classes indirectly (by trust); the filing does not report a price. New position of 97,200 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 24, 2026 |
| Jan 21, 2026 | Open-market purchase | Ramtin Agah (Chief Medical Officer and Director) bought 10,000 shares at about $1.00 ($10K) in an open-market purchase. Holdings up 1% to 798,460 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 22, 2026 |
| Dec 31, 2025 | Open-market purchase | Ramtin Agah (Chief Medical Officer and Director) bought 9,795 shares at $0.8600 ($8K) in an open-market purchase. Holdings up 1% to 788,460 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 5, 2026 |
| Dec 30, 2025 | Open-market purchase | Ramtin Agah (Chief Medical Officer and Director) bought 205 shares at about $0.8300 ($170) in an open-market purchase. Holdings up <1% to 778,665 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 2, 2026 |
| Dec 18, 2025 | Open-market purchase | Shaun Bagai (CEO and Director) bought 5,000 shares at $0.9000 ($5K) in an open-market purchase. Holdings up 1% to 340,040 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 22, 2025 |
| Dec 17, 2025 | Open-market purchase | Shaun Bagai (CEO and Director) bought 5,000 shares at $0.8500 ($4K) in an open-market purchase. Holdings up 2% to 335,040 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 19, 2025 |
| Dec 16, 2025 | Open-market purchase | Ramtin Agah (Chief Medical Officer and Director) bought 12,000 shares at $0.8500 ($10K) in an open-market purchase. Holdings up 2% to 778,460 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 17, 2025 |
| Dec 5, 2025 | Open-market purchase | Ramtin Agah (Chief Medical Officer and Director) bought 10,000 shares at $0.9600 ($10K) in an open-market purchase. Holdings up 1% to 766,460 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 8, 2025 |
| Nov 21–24, 2025 | Open-market purchase | Ramtin Agah (Chief Medical Officer and Director) bought 22,000 shares between Nov 21, 2025 and Nov 24, 2025 at $0.8000 ($18K) in an open-market purchase. Holdings up 3% to 756,460 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 24, 2025 |
11 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow RNXT in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.